In the article by P. A. Davol et al., titled “Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer,” which appeared in the October 15, 2003 issue of Cancer Research (pp. 6772–6783), Table 6 was omitted. Table 6 appears below.

In the article by H. M. Sowter et al., titled “Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia,” which appeared in the October 1, 2003 issue of Cancer Research (pp. 6130–6134), Raju Raval and John Moore’s middle initials were omitted. The correct author list is as follows: Heidi M. Sowter, Raju R. Raval, John W. Moore, Peter J. Ratcliffe, and Adrian L. Harris.

Table 6

Multivariate cox models of RFS and DSS

RFSDSS
ModelsaHR              b(95% CI)PHR              b(95% CI)P
Base Model       
 Nodal status 6.4 (1.7–24) 0.006 11 (1.5–84) 0.019 
 Tumor stage 5.4 (0.75–39) 0.095 10 (1.03–100) 0.047 
 Therapy 6.1 (0.88–42 0.068 5.7 (0.45–72) 0.095 
with SRcont       
 Shc Ratio 12.7 (1.7–93) 0.012 28.3 (2.2–370) 0.011 
 Nodal status 8.2 (2.5–27) 0.001 9.0 (1.9–43) 0.006 
 Therapy 6.7 (0.98–45) 0.053 10 (0.75–132) 0.081 
with SRcat       
 Shc Ratiolow/high 0.088 (0.011–0.72) 0.024    
 Shc Ratiointer/high 0.20 (0.050–0.83 0.029    
 Nodal status 3.6 (1.05–12) 0.042    
 Therapy 5.7 (0.84–38) 0.074    
RFSDSS
ModelsaHR              b(95% CI)PHR              b(95% CI)P
Base Model       
 Nodal status 6.4 (1.7–24) 0.006 11 (1.5–84) 0.019 
 Tumor stage 5.4 (0.75–39) 0.095 10 (1.03–100) 0.047 
 Therapy 6.1 (0.88–42 0.068 5.7 (0.45–72) 0.095 
with SRcont       
 Shc Ratio 12.7 (1.7–93) 0.012 28.3 (2.2–370) 0.011 
 Nodal status 8.2 (2.5–27) 0.001 9.0 (1.9–43) 0.006 
 Therapy 6.7 (0.98–45) 0.053 10 (0.75–132) 0.081 
with SRcat       
 Shc Ratiolow/high 0.088 (0.011–0.72) 0.024    
 Shc Ratiointer/high 0.20 (0.050–0.83 0.029    
 Nodal status 3.6 (1.05–12) 0.042    
 Therapy 5.7 (0.84–38) 0.074    

a Model development is described in Methods. Wald-test values of P < 0.05 are indicated in bold type. Models use the Shc Ratio as an indexed categorical variable (SRcat) (see Table 4), and also as a continuous variable (SRcont).

b HR for SRcat compares the hazard of low to high and intermediate (inter) to high, as in Table 4. HR for SRcont reflects the full observed range of Shc Ratios. HR compares >3 positive nodes to 0 positive nodes: Stage III to Stage I; T4 to T1; for Therapy, surgery with radiation to surgery alone.